middle.news
Mayne Pharma Clarifies FDA Letter Impact Amid Share Price Drop
2:33am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Mayne Pharma Clarifies FDA Letter Impact Amid Share Price Drop
2:33am on Monday 2nd of June, 2025 AEST
Key Points
Share price dropped from $6.79 to $5.97 amid high trading volume
FDA Untitled Letter on NEXTSTELLIS® promotional claims publicly released
Mayne Pharma denies any undisclosed price-sensitive information
Company preparing near-final response to FDA within required timeframe
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE